首页> 美国卫生研究院文献>other >Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication
【2h】

Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication

机译:未经药物治疗的精神分裂症患者的基底神经节体积与抗精神病药物的治疗反应有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia. Basal ganglia volumes included the bilateral caudate, putamen, and pallidum and were measured using the Freesurfer automated segmentation pipeline in 23 subjects. Also, baseline symptom severity, duration of illness, age, gender, time off medication, and exposure to previous antipsychotic were measured. Treatment response was significantly correlated with all three regions of the bilateral basal ganglia (caudate, putamen, and pallidum), baseline symptom severity, duration of illness, and age but not gender, time off antipsychotic medication, or exposure to previous antipsychotic medication. The caudate volume was the basal ganglia region that demonstrated the strongest correlation with treatment response and was significantly negatively correlated with patient age. Caudate volume was not significantly correlated with any other measure. We demonstrated a novel finding that the caudate volume explains a significant amount of the variance in treatment response over the course of six-weeks of risperidone pharmacotherapy even when controlling for baseline symptom severity and duration of illness.
机译:我们调查了精神分裂症未经药物治疗的患者的非典型抗精神病药物利培酮基础神经节容量与治疗反应之间的关系。基底神经节体积包括双侧尾状,壳状核和苍白质,并使用Freesurfer自动分割管线对23位受试者进行了测量。此外,还测量了基线症状的严重程度,疾病的持续时间,年龄,性别,停药时间以及接触过先前的抗精神病药。治疗反应与双侧基底神经节的所有三个区域(尾状,壳状核和苍白质),基线症状严重程度,疾病持续时间和年龄均显着相关,但与性别,停用抗精神病药物的时间或接触过先前的抗精神病药物无关。尾状体积是基底神经节区域,显示与治疗反应之间最强的相关性,与患者年龄显着负相关。尾鳍体积与其他任何指标均无显着相关性。我们证明了一个新颖的发现,即使控制基线症状的严重程度和病程,尾核体积在利培酮药物治疗六周的过程中也能说明治疗反应的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号